血栓和止血生物标记市场机会、成长动力、产业趋势分析和 2024 年至 2032 年预测

2023 年，全球血栓和止血生物标记市场估值为52 亿美元，预计2024 年至2032 年复合年增长率为5.8%。 、生物标记研究的进步、以及个人化医疗的日益普及。人们对凝血相关病症的早期检测和管理的认识不断增强，进一步支持了市场的扩张。

该市场根据产品分为分析仪和试剂及消耗品，后者在 2023 年占据主导地位，收入达 33 亿美元。试剂和耗材对于诊断和研究目的至关重要，包括用于检测和分析凝血障碍生物标记的检测试剂盒、化学物质和缓衝液。对准确、快速的诊断工具的需求推动了对这些产品的需求，以识别深部静脉栓塞和肺栓塞等疾病。纤维蛋白原、D-二聚体和凝血酶原时间等关键生物标记有助于监测凝血障碍并指导抗凝血治疗。

市场也根据测试地点分为临床实验室测试和现场护理测试。 2023 年，临床实验室检测占主导地位，占 64.1% 这些检测，包括凝血酶原时间、活化部分凝血活酶时间和血小板功能分析，对于诊断凝血异常和评估出血风险至关重要。心血管疾病发病率的不断上升、人口老化和肥胖率的增加正在推动对这些诊断服务的需求。这些检查不仅有助于评估凝血途径，还支持血栓形成预防策略和抗凝血治疗的有效管理。

美国血栓和止血生物标记市场预计将以5.8% 的复合年增长率增长，到2032 年将达到30 亿美元。增长。研发方面的强劲投资以及精准医疗的广泛采用，推动了对血栓和止血生物标记的需求。领先的生物技术和製药公司的存在进一步加速了生物标记发现和商业化的进步，重点关注早期检测和个人化治疗。此外，不断增加的医疗支出和有利的监管框架促进了创新诊断工具在临床实践中的采用。现场护理测试设备和非侵入性诊断方法的使用不断增加，增强了患者护理，同时推动了市场扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 心血管疾病盛行率上升
    • 生物标记测试的技术进步
    • 个人化医疗需求不断成长
  • 产业陷阱与挑战
    • 生物标记检测成本高
    • 新兴市场意识有限
• 成长潜力分析
• 监管环境
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：依产品分类，2021-2032 年

• 主要趋势
• 分析仪
• 试剂及耗材

第 6 章：市场估计与预测：按测试地点，2021-2032 年

• 主要趋势
• 临床实验室测试
• 现场护理测试

第 7 章：市场估计与预测：依测验类型，2021-2032

• 主要趋势
• D-二聚体
• 抗凝血酶III
• 纤溶酶原
• 可溶性纤维蛋白
• 因子VIII
• 凝血酶后 (PT)
• 活化部分凝血活酶时间 (APTT) 测试
• 其他测试类型

第 8 章：市场估计与预测：按应用划分，2021-2032 年

• 主要趋势
• 深部静脉血栓 (DVT)
• 肺栓塞（PE）
• 瀰漫性血管内凝血 (DIC)
• 其他应用

第 9 章：市场估计与预测：依最终用途，2021-2032 年

• 主要趋势
• 医院和诊所
• 诊断实验室
• 其他最终用户

第 10 章：市场估计与预测：按地区划分，2021-2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：公司简介

• Abbott Laboratories
• ARUP Laboratories
• Biomedica Diagnostics
• BioMerieux
• Cincinnati Children's Hospital Medical Center
• Cleveland Clinic Laboratories
• Diazyme Laboratories
• F. Hoffmann-La Roche
• HORIBA
• Mayo Clinic Laboratories
• QuidelOrtho
• Siemens Healthineers
• Thermo Fisher Scientific
• Werfen

The Global Thrombosis And Hemostasis Biomarkers Market was valued at USD 5.2 billion in 2023 and is projected to grow at a CAGR of 5.8% from 2024 to 2032. This growth is driven by the increasing prevalence of cardiovascular and clotting disorders, advancements in biomarker research, and the rising adoption of personalized medicine. The market's expansion is further supported by growing awareness of early detection and management of coagulation-related conditions.

The market is segmented based on products into analyzers and reagents & consumables, with the latter dominating in 2023, accounting for USD 3.3 billion in revenue. Reagents and consumables are crucial for diagnostic and research purposes, encompassing assay kits, chemicals, and buffers used to detect and analyze biomarkers for clotting disorders. The demand for these products is fueled by the need for accurate and rapid diagnostic tools to identify conditions such as deep vein thrombosis and pulmonary embolism. Key biomarkers like fibrinogen, D-dimer, and prothrombin time help monitor coagulation disorders and guide anticoagulant therapies.

The market is also categorized by test location into clinical laboratory tests and point-of-care tests. Clinical laboratory tests held a dominant share of 64.1% in 2023. These tests, including prothrombin time, activated partial thromboplastin time, and platelet function analysis, are vital for diagnosing clotting abnormalities and assessing bleeding risks. The growing incidence of cardiovascular diseases, an aging population, and increasing obesity rates are driving demand for these diagnostic services. These tests not only aid in evaluating coagulation pathways but also support the effective management of thrombosis prevention strategies and anticoagulant treatments.

The U.S. thrombosis and hemostasis biomarkers market is projected to grow at a CAGR of 5.8%, reaching USD 3 billion by 2032. A well-established market foundation, combined with a high prevalence of cardiovascular diseases, positions the U.S. for significant growth. Robust investments in research and development, along with the widespread adoption of precision medicine, drive demand for thrombosis and hemostasis biomarkers. The presence of leading biotechnology and pharmaceutical companies further accelerates advancements in biomarker discovery and commercialization, focusing on early detection and personalized therapies. Moreover, increasing healthcare expenditures and a favorable regulatory framework promote the adoption of innovative diagnostic tools in clinical practices. The growing use of point-of-care testing devices and non-invasive diagnostic methods enhances patient care while fueling market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cardiovascular diseases
    • 3.2.1.2 Technological advancements in biomarker testing
    • 3.2.1.3 Growing demand for personalized medicine
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of biomarker testing
    • 3.2.2.2 Limited awareness in emerging markets
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates & Forecast, By Product, 2021-2032 ($ Mn)

• 5.1 Key trends
• 5.2 Analyzers
• 5.3 Reagents & Consumables

Chapter 6 Market Estimates & Forecast, By Test Location, 2021-2032 ($ Mn)

• 6.1 Key trends
• 6.2 Clinical laboratory tests
• 6.3 Point-of-care tests

Chapter 7 Market Estimates & Forecast, By Test Type, 2021-2032 ($ Mn)

• 7.1 Key trends
• 7.2 D-dimer
• 7.3 Anti-thrombin III
• 7.4 Plasminogen
• 7.5 Soluble fibrin
• 7.6 Factor VIII
• 7.7 Post-Thrombin (PT)
• 7.8 Activated Partial Thromboplastin Time (APTT) test
• 7.9 Other test types

Chapter 8 Market Estimates & Forecast, By Application, 2021-2032 ($ Mn)

• 8.1 Key trends
• 8.2 Deep Vein Thrombosis (DVT)
• 8.3 Pulmonary Embolism (PE)
• 8.4 Disseminated Intravascular Coagulation (DIC)
• 8.5 Other applications

Chapter 9 Market Estimates & Forecast, By End Use, 2021-2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals and clinics
• 9.3 Diagnostic laboratories
• 9.4 Other end users

Chapter 10 Market Estimates & Forecast, By Region, 2021-2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East & Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 ARUP Laboratories
• 11.3 Biomedica Diagnostics
• 11.4 BioMerieux
• 11.5 Cincinnati Children's Hospital Medical Center
• 11.6 Cleveland Clinic Laboratories
• 11.7 Diazyme Laboratories
• 11.8 F. Hoffmann-La Roche
• 11.9 HORIBA
• 11.10 Mayo Clinic Laboratories
• 11.11 QuidelOrtho
• 11.12 Siemens Healthineers
• 11.13 Thermo Fisher Scientific
• 11.14 Werfen